Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis by Mou, Haiwei et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Program in Bioinformatics and Integrative 
Biology Publications and Presentations 
Program in Bioinformatics and Integrative 
Biology 
2017-04-04 
Genetic disruption of oncogenic Kras sensitizes lung cancer cells 
to Fas receptor-mediated apoptosis 
Haiwei Mou 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/bioinformatics_pubs 
 Part of the Cancer Biology Commons, and the Cell Biology Commons 
Repository Citation 
Mou H, Moore J, Malonia SK, Li Y, Ozata DM, Hough S, Song C, Smith JL, Fischer AH, Weng Z, Green MR, 
Xue W. (2017). Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-
mediated apoptosis. Program in Bioinformatics and Integrative Biology Publications and Presentations. 
https://doi.org/10.1073/pnas.1620861114. Retrieved from https://escholarship.umassmed.edu/
bioinformatics_pubs/117 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Program in 
Bioinformatics and Integrative Biology Publications and Presentations by an authorized administrator of 
eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu. 
Genetic disruption of oncogenic Kras sensitizes lung
cancer cells to Fas receptor-mediated apoptosis
Haiwei Moua,1, Jill Mooreb,1, Sunil K. Maloniac,1, Yingxiang Lib,d, Deniz M. Ozataa, Soren Hougha, Chun-Qing Songa,
Jordan L. Smitha, Andrew Fischere, Zhiping Wengb, Michael R. Greenc,f,2, and Wen Xuea,c,g,2
aRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605; bProgram in Bioinformatics and Integrative Biology,
University of Massachusetts Medical School, Worcester, MA 01605; cDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Medical
School, Worcester, MA 01605; dDepartment of Bioinformatics, School of Life Science and Technology, Tongji University, Shanghai 200092, People’s Republic
of China; eDepartment of Pathology, University of Massachusetts Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA
01605; fHoward Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01604; and gProgram in Molecular Medicine,
University of Massachusetts Medical School, Worcester, MA 01605
Contributed by Michael R. Green, December 28, 2016 (sent for review July 14, 2016; reviewed by Michael T. Hemann and Andrea Ventura)
Genetic lesions that activate KRAS account for∼30% of the 1.6million
annual cases of lung cancer. Despite clinical need, KRAS is still undrug-
gable using traditional small-molecule drugs/inhibitors. When onco-
genic Kras is suppressed by RNA interference, tumors initially regress
but eventually recur and proliferate despite suppression of Kras. Here,
we show that tumor cells can survive knockout of oncogenic Kras,
indicating the existence of Kras-independent survival pathways. Thus,
even if clinical KRAS inhibitors were available, resistance would re-
main an obstacle to treatment. Kras-independent cancer cells exhibit
decreased colony formation in vitro but retain the ability to form
tumors in mice. Comparing the transcriptomes of oncogenic Kras cells
and Kras knockout cells, we identified 603 genes that were specifi-
cally up-regulated in Kras knockout cells, including the Fas gene,
which encodes a cell surface death receptor involved in physiological
regulation of apoptosis. Antibodies recognizing Fas receptor effi-
ciently induced apoptosis of Kras knockout cells but not oncogenic
Kras-expressing cells. Increased Fas expression in Kras knockout cells
was attributed to decreased association of repressive epigenetic
marks at the Fas promoter. Concordant with this observation, treat-
ing oncogenic Kras cells with histone deacetylase inhibitor and Fas-
activating antibody efficiently induced apoptosis, thus bypassing
the need to inhibit Kras. Our results suggest that activation of
Fas could be exploited as an Achilles’ heel in tumors initiated by
oncogenic Kras.
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Lung cancer is a leading cause of cancer death, accounting for∼1.3 million deaths worldwide each year (1). Non–small-cell
lung cancer (NSCLC), the most common subtype, is associated
with frequent mutations in KRAS (∼30%). KRAS is also frequently
mutated in other tumor types, including pancreatic (>90%) and
colon (∼30%) cancer (2). Although various pharmacological in-
hibitors are being developed for RAS, especially for the mutant
KRASG12C (3–5), these small molecules have not been tested in
the clinic (6, 7). As a result, advanced oncogenic KRAS lung
cancers are usually treated with conventional therapy such as ra-
diation and chemotherapy, often with limited success (1, 8).
Controlled expression of oncogenic RAS cDNA in mouse
models of melanoma, lung, breast, and pancreatic cancer has
shown that the withdrawal of oncogenic RAS results in complete
tumor regression (9–11). This phenomenon, known as “oncogene
addiction,” suggests that oncogenic KRAS alleles (e.g., KRASG12D)
not only initiate tumorigenesis but also play a crucial role in tumor
maintenance. To recapitulate KRAS oncogene addiction in a
mouse model of lung cancer, we developed a conditional Kras
shRNA system (shKras) to knock down Kras in KrasG12D/+;p53−/−
(KP) cell lines derived from a mouse lung tumor (12–14). When
we orthotopically transplanted shKras KP cells into immuno-
compromised mice, we found that Kras-driven lung tumors can
escape oncogene addiction and become independent of Kras
signaling (termed Kras independence) (15, 16).
Because shRNAs targeting Kras do not completely eliminate
Kras expression, residual Kras in cells could contribute to Kras-
independent tumor growth. The best way to rule out this possibility
is to genetically delete Kras altogether. Unfortunately, the Kras
knockout mouse is embryonically lethal (17), and genetic disruption
of KRAS—or other oncogenes—in human cells remains a chal-
lenge due to the low efficiency of homologous recombination using
traditional gene-targeting technology. We recently showed that
CRISPR (18) can be used to efficiently and specifically edit cancer
genes in adult mice in a fraction of the time and cost of traditional
mouse models (19–21). CRISPR therefore provides a flexible ge-
netic system to manipulate the function of cancer genes (22, 23).
Previous work has shown that oncogenic KRAS epigenetically
silences Fas expression (24, 25). In addition, RAS directs epige-
netic silencing of Fas through a highly ordered pathway that cul-
minates in methylation of the Fas promoter (26, 27). It remains
unexplored whether Fas can be restored by genetic inactivation of
oncogenic RAS.
Significance
Oncogenic KRAS underlies 30–90%of lung, colon, and pancreatic
cancers, but despite more than 30 y of research, clinical inhibitors
of KRAS—and potential resistance mechanisms—remain elusive.
Using CRISPR-mediated genome editing of oncogenic Kras, we
show that some lung cancer cells can survive Kras knockout,
indicating the existence of mechanisms that allow tumors to
escape Kras oncogene addiction. We identify genes highly
expressed in Kras knockout cells, including the Fas receptor
gene. Antibodies that activate Fas receptor selectively induced
apoptosis in Kras-independent lung cancer cells, suggesting a
potential strategy for combinatorial therapies against Kras-
driven tumors. These findings have direct translational implica-
tions for the treatment of lung cancer and other KRAS mutant
cancer types.
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Here, we use CRISPR to establish viable Kras knockout (Kras−/−)
lung cancer cell lines from parental oncogenic Kras (KrasG12D/+)
cells. While investigating the mechanism of Kras-independent tu-
morigenesis in this model, we identified Fas among the genes most
highly regulated by Kras. Fas (also known as CD95, APO-1, and
TNFRSF6) encodes a cell surface death receptor that triggers
apoptosis upon binding by its cognate ligand, Fas ligand (FasL) (or
CD95L), and plays critical roles in the immune elimination of
cancer cells (28, 29). In both mouse and human lung cancer cells,
genetic disruption of Kras elevated Fas expression on the cell sur-
face and increased sensitivity to Fas-mediated apoptosis, thereby
demonstrating a selective vulnerability of Kras-independent cells.
Consistent with previous work showing that oncogenic KRAS epi-
genetically silences Fas expression (24, 25), we show that Fas is
activated in Kras−/− cells by loss of both Dnmt1 and Ezh2 re-
cruitment and repressive epigenetic marks of the Fas promoter.
Remarkably, treatment of parental KrasG12D/+ cells with pharma-
cological histone deacetylase (HDAC) inhibitors not only increased
Fas levels but also sensitized cells to Fas-mediated apoptosis. These
results suggest a combinatorial strategies for targeted elimination of
Kras-independent and oncogenic Kras lung cancer cells.
Results
Kras Knockout Murine Lung Cancer Cells Are Viable and Can Form
Tumors in Mice. Our previous study showed that shRNAs target-
ing Kras do not completely eliminate Kras in cells (16), hence the
residual Kras might contribute to Kras independence. We there-
fore used CRISPR-based method to genetically disrupt oncogenic
Kras in two independent mouse KrasG12D/+;p53−/− lung cancer
cell lines (termed KP1 and KP2) (30–32). Lentiviral vector
(lentiCRISPR) with puromycin selection marker, as described
previously (33), was used to deliver Cas9 and a sgRNA targeting
KrasG12D (sgKras) into the target cells (Fig. 1A). The puromycin-
resistant single-cell clones expressing sgKras were screened for Kras
elimination and specific indel mutations at target loci. Immunoblot
analysis of single clones expressing sgKras, using anti-Kras antibody
showed the total absence of endogenous Kras protein (Fig. 1B).
Furthermore, deep-sequencing analysis revealed 2-nt deletions at
the G12D allele (Fig. 1C). Although we designed sgKras to target
the G12D sequence (Fig. 1A), a 1-nt deletion was detected at the
wild-type allele (Fig. 1C). This confirmed that CRISPR can tolerate
mismatch between the sgRNA and target site, consistent with
known CRISPR off-target effects (34). These biallelic deletions shift
the reading frame of Kras mRNA, likely resulting in premature
termination of translation and nonsense-mediated decay of the Kras
mRNA, as shown in immunoblots of Fig. 1B. We therefore defined
these clones as Kras−/− (Kras knockout) cells.
The Kras−/− clones show markedly reduced proliferation and
colony-forming ability compared with KrasG12D/+ (Fig. 1D), fur-
ther validating the role of Kras in cell proliferation in lung cancer.
Nevertheless, Kras−/− cells are viable and form small colonies in an
in vitro colony formation assay (Fig. 1D).
To test whether Kras−/− cells can form tumors in vivo, we
transplanted KrasG12D/+ and Kras−/− cells s.c. in immunosup-
pressed nude mice. Kras−/− cells formed tumors (n = 3 mice), but
detection of tumor was much slower (60 d) compared with
KrasG12D/+ cells (20 d) (Fig. S1A). In addition, we observed gland-
like structure and more cytoplasm of Kras−/− tumor by H&E
staining (Fig. S1B), providing availability to further investigate
Kras−/− tumor pathology. Taken together, these data show that
cancer cells derived from oncogenic Kras tumors can indeed es-
cape complete genetic disruption of Kras, and the resulting Kras-
independent cancer cells can still form tumors in nude mice.
Transcriptome Analysis of Kras Knockout Cells Revealed Distinct Gene
Signatures. To explore the mechanisms of Kras independence,
RNA sequencing (RNA-seq) was performed in KrasG12D/+ and
Kras−/− cells. Bioinformatic analysis of RNA-seq data identified
603 up-regulated genes and 216 down-regulated genes in Kras−/−
compared with KrasG12D/+ cells (absolute fold change, >2; value
of P < 0.05; Fig. 2 A and B), which were consistently up-regulated
(down-regulated) in both pairs of KrasG12D/+ and Kras−/− cells
(KP1 and KP2, Fig. 2 A and B). These genes are listed in Dataset
S1 (“DEG differentially expressed genes”). We then analyzed
whether these differentially expressed genes were enriched in any
gene ontology or pathways, using the Gene Set Enrichment
Analysis (GSEA) and the Molecular Signature Database (MSigDB)
(35). The 603 up-regulated genes were enriched in many cancer-
related pathways (Fig. 2C), most notably epithelial to mesenchymal
transition (q value = 7.25E-53), YAP (q value = 8.30E-18) as well as
sets of genes that are down-regulated upon activation of an onco-
genic form of KRAS (q value = 1.08E-29). Conversely, the 216
down-regulated genes are enriched in the sets of genes up-regulated
by KRAS activation (q value = 3.27E-9). The entire list of enriched
gene sets and pathways are provided in Dataset S1 (“Panther or
GSEA”). We further confirmed that mRNA levels of RAS
ortholog genes (Hras and Nras) did not change in Kras−/− cells
(Fig. 2D). In addition, the sgKras did not induce indel mutations
at Hras and Nras genomic loci (Fig. S2 A and B). These data
suggest that Hras and Nras do not compensate for the in-
activation of oncogenic Kras in this model.
To narrow down the list of differentially expressed genes and
identify a possible secondary target in Kras−/− cells, we made the
following assumptions: (i) the gene should be up-regulated upon
Kras knockout, (ii) the gene should encode a plasma mem-
brane protein, allowing it to be more easily targeted. Out of the
Fig. 1. CRISPR-mediated Kras knockout in Kras-driven mouse lung adeno-
carcinoma cells. (A) Schematic diagram of CRISPR sgRNA design targeting exon
2 of the mutant Kras allele (KrasG12D/+). Codon 12 is underlined. “GAT”
encodes G12D mutation. Red arrowhead indicates the Cas9 cutting site. (B)
Immunoblot demonstrating total Kras protein levels in KP1 and KP2 clone
pairs. Each pair included two clones: one parental (KP1/KP2) and one Kras
knockout (KP1 clone/KP2 clone). Hsp90 was used as a loading control. (C)
Deep-sequencing analysis showing small deletions induced by CRISPR in a
representative clone. (Upper) Representative IGV plots. Black bars denote
deletions (purple circle). The red “T” is the G12D mutation. The HindIII site
(“C” SNP) was engineered in the original KrasG12D/+ mouse model. (Lower)
CRISPR induced a 2-nt deletion in the KrasG12D allele and a 1-nt deletion in the
wild-type Kras allele. (D) Colony formation assay to examine the ability of
KrasG12D/+ and Kras−/− cells to form colonies. Cells were seeded in six-well
plates at 1,000 cells per well, cultured for 5 d and stained with crystal violet.
Inset shows small Kras−/− colonies.
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603 up-regulated genes, 189 were annotated as plasma mem-
brane proteins (Dataset S1). To identify up-regulated genes with
the most significant P values and largest fold changes, we ranked
each of the 189 genes by its average rank of P value. Fold change
of the top 10 genes in Kras−/− clones is shown in Fig. 2E. We
further analyzed the expression profile of these top 10 candidate
genes using The Cancer Genome Atlas (TCGA) datasets (lung
adenocarcinoma vs. normal), and found that 7 candidate genes
were significantly down-regulated in tumor samples (Fig. S2C).
This analysis indicated that these candidates may have a putative
role in development or progression of human lung cancer.
Moreover, some of these of the candidates, such as DLC1 (36),
FAT4 (37), and FAS (28), are well-known tumor suppressors.
Fas Is Up-Regulated in Kras-Independent Cancer Cells. Among the top
10 genes highly expressed in Kras−/− cells from the RNA-seq, we
focused to investigate Fas (which encodes the Fas receptor) for
two reasons. First, the Fas receptor triggers apoptosis through cell-
intrinsic pathway (38, 39), and it has been implicated in various
malignancies (28), hence an attractive therapeutic target. Second,
based on previous work (26, 27), Fas expression has been shown to
be regulated by Ras-dependent pathways. Following validation of
RNA-seq data, the quantitative RT-PCR (qRT-PCR) and im-
munoblot analysis in parental KrasG12D/+ and Kras−/− cells
revealed that KrasG12D/+ cells expressed very low levels of Fas,
whereas Kras−/− cells showed a marked increase in Fas mRNA
and protein levels (Fig. 3 A and B). Oncogenic RAS activates
several downstream signaling pathways, including the MAPK and
phosphoinositide 3-kinase (PI3K)/AKT pathways (2). Consistent
with previous reports, that Kras-dependent silencing of Fas is
partly mediated by MAPK pathway (26), we also observed an
increased level of Fas mRNA in KrasG12D/+ cells treated with
MEK inhibitor U0126 (Fig. 3C).
Previous studies have shown that expression of oncogenic RAS
in mouse NIH 3T3 cells transcriptionally silenced Fas, thereby
preventing Fas ligand-induced apoptosis (25). Subsequent studies
using genome-wide RNAi screens identified cofactors required for
RAS-mediated epigenetic silencing of Fas (27). Kras directs epi-
genetic silencing of Fas through an ordered pathway that culmi-
nates in methylation of the Fas promoter and recruitment of
corepressor complex (26, 27). Because KrasG12D/+ cells expressed
relatively lower levels of Fas mRNA, we hypothesized that Fas
could be transcriptionally silenced in these cells. The Kras-medi-
ated epigenetic silencing of Fas requires two major events, first is
the methylation of promoter by DNAmethyltransferase, DNMT1,
and then trimethylation of histone H3 at lysine 27 (H3K27me3)
catalyzed by the histone methyltransferase Ezh2, a component of
polycomb repressive complex 2 (26, 27). shRNA-mediated knock-
down of either Ezh2 or Dnmt1 significantly increased Fas ex-
pression in KrasG12D/+ cells, suggesting that both factors mediate
Kras-dependent silencing of Fas (Fig. S3A).
We then measured the levels of Dnmt1 and EZH2 and their
corresponding epigenetic marks at the Fas promoter in KrasG12D/+
and Kras−/− cells. Chromatin immunoprecipitation (ChIP) revealed
a significant enrichment of EZH2 and H3K27me3 at the Fas
promoter in KrasG12D/+ cells compared with Kras−/− cells (Fig. 3 D
and E). Consistent with previous studies (27), Dnmt1 and DNA
methylation were also significantly enriched at the Fas promoter in
KrasG12D/+ cells compared with Kras−/− cells (Fig. 3 F and G).
Thus, the high levels of Fas mRNA in Kras−/− cells is consistent
with low levels of Dnmt1 and EZH2 and their corresponding
epigenetic marks at the Fas promoter. Moreover, we found that
H3K4 acetylation was enriched at the Fas promoter in Kras−/− cells
(Fig. S3B), consistent with its transcriptionally active state. These
data indicate that genetic inactivation of oncogenic Kras leads to
transcriptional activation and restoration of Fas expression.
Fas-Mediated Apoptosis Can Eliminate Kras-Independent Cells. Be-
cause Fas is a major mediator of apoptosis on the cell surface, we
hypothesized that activation of Fas might selectively trigger apo-
ptosis of Kras−/− cells. Using fluorescence-activated cell sorting
(FACS), we confirmed that the Fas receptor is highly expressed on
Fig. 2. Identification of KRAS independence genes by RNA-seq. (A) RNA-seq
in KrasG12D/+ and Kras−/− cell pairs to identify Kras-independent genes. Heat
map shows the clustering of differentially expressed genes. n = 2 for KP2
Kras−/−, n = 3 for other groups. (B) Volcano plot of differentially expressed
genes in Kras−/− vs. KrasG12D cells. A total of 603 genes showed increased
expression in both KP1 and KP2 pairs; 216 genes showed decreased expres-
sion. (C) Selected GSEA dataset. GSEA analysis identified gene sets enriched
in up-regulated genes (up in Kras−/− cells) or in down-regulated genes (down
in Kras−/− cells). (D) RNA-seq reads showing the relative expression of Ras
family genes Hras and Nras in Kras−/− cells. (E) Top 10 candidate genes in the
“membrane protein” category.
Fig. 3. The Fas receptor is up-regulated in Kras−/− cells. (A) qPCR showing
up-regulation of Fas mRNA in Kras−/− cells. (B) Immunoblot demonstrating
Fas protein levels in KrasG12D/+and Kras−/− cells. Mouse 3T3 fibroblast cells
were used as a positive control for Fas expression. (C) qPCR showing an in-
crease in Fas mRNA upon treatment of MEK inhibitor U0126 in KrasG12D/+
cells at 48 h. (D–F) ChIP assays demonstrating the relative binding of EZH2,
DNMT1, and enrichment of H3K27Me3 on Fas promoter in KrasG12D/+ and
Kras−/− cells. (G) Methylated DNA immunoprecipitation (MeDIP) assays
demonstrating the relative enrichment of 5-methyl cytosine on Fas promoter
in KrasG12D/+ and Kras−/− cells. Error bars represent SD (n = 3). **P < 0.01.
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the surface of Kras−/− cells compared with KrasG12D/+ cells (Fig. 4A).
As reported before, binding of Fas ligand or Fas-activating anti-
bodies to Fas receptor triggers apoptosis through cell-intrinsic
pathway (28). We tested whether a Fas-activating antibody can in-
duce Fas-mediated cell death in Kras−/− cells. When incubating cells
with an antibody (Jo2), which binds and activates mouse Fas re-
ceptor (28), we observed that many Kras−/− cells became round in
shape and detached from the plate, compared with few dead
KrasG12D/+ cells (Fig. 4B). Furthermore, we measured the apoptotic
cells by Annexin V staining using FACS and observed that ∼50% of
Jo2-treated Kras−/− cells were Annexin V positive compared with
∼5% of Jo2-treated KrasG12D/+ cells (Fig. 4C andD), demonstrating
that Fas activation can selectively induce apoptosis in Kras−/− cells
over the oncogenic KrasG12D/+ cells. These results demonstrated
that, in the absence of Kras, Fas expression is significantly restored,
conferring sensitivity to Fas antibody-induced apoptosis.
To investigate whether the Fas restoration can be rescued by
oncogenic RAS, we reintroduced an oncogenic RAS cDNA in
Kras−/− cells. Because Kras−/− cells constitutively expressed Cas9
and Kras sgRNA, these cells are refractory to a KrasG12D cDNA.
However, our deep-sequencing data showed that the Hras allele is
not affected by the Kras sgRNA. We introduced oncogenic HRAS
in Kras−/− cells through retrovirus expressing a HRAS-V12 cDNA
(40). Consistent with our previous results of Fas restoration upon
loss of Kras (Fig. 3), overexpression of HRAS-V12 in Kras−/− cells
led to dramatic decrease in Fas mRNAs (Fig. S4A). Moreover,
Fas receptor-mediated apoptosis triggered by the Jo2 antibody
was fully rescued in Kras−/− cells expressing HRAS-V12 (Fig.
S4B). Thus, reintroduction of oncogenic RAS rapidly suppresses
Fas expression in nearly all Kras−/− cells. Together, our data
suggest Fas activating antibody as a potential therapeutic strategy
to kill Kras-independent cancer cells following Kras silencing.
KRAS Knockout Human Cancer Cells Are Sensitive to FAS-Mediated
Apoptosis. To assess whether CRISPR can edit KRAS in human
NSCLC cells carrying KRAS mutations, we chose A549 human
lung adenocarcinoma cells, which harbor a homozygous KRASG12S
allele (41). Using similar approach as described above, A549 cells
were infected with lentivirus expressing Cas9 and a guide RNA
that targets human KRAS (sgKRAS). sgKRAS induced genome
editing (Fig. S5) and significantly reduced total KRAS protein
level in a cell population (Fig. 5A). Concordant with our results in
mouse lung cancer cells, we found that some A549 cells survive
KRAS knockout. Likewise, we also observed an increase in FAS
mRNA (Fig. 5B) and receptor level (Fig. 5C) in sgKRAS-
expressing A549 cells.
To explore methods to overcome resistance to KRAS knockout
in human cells, we hypothesized that activation of FAS could also
selectively induce apoptosis in KRAS knockout A549 cells. By
incubating cells with an activating antibody for human FAS (clone
EOS9.1), we observed that KRAS knockout cells are sensitive to
FAS-mediated apoptosis (Fig. 5 D–F). These results indicate a
potential strategy to overcome resistance for KRAS inhibition in
human NSCLC by activating FAS.
To ensure that the increased sensitivity to FAS activation is
indeed a phenotype of CRISPR-mediated KRAS knockout, we
used previously reported DLD1 colon cancer cells (KRASG13D/+
vs. KRAS−/+) generated by targeting G13D allele by traditional
homologous recombination (42). As expected, KRAS−/+ DLD1
cells also exhibited increased sensitivity to FAS antibody-induced
apoptosis. As shown in Fig. 6 A and B and Fig. S6, incubation of
FAS-activating antibody with KRAS knockout (KRAS−/+) DLD1
cells, markedly increased Annexin V-positive apoptotic cells. This
suggests that KRAS knockout leading to restored FAS expression
is a general phenomenon, and that KRAS silencing confers sen-
sitivity to FAS-induced apoptosis both in lung cancer cells edited
by CRISPR and in colon cancer cells generated by traditional
homologous recombination. Therefore, this conserved mechanism
may provide a therapeutic strategy to suppress tumor relapse
alongside future generation of KRAS inhibitors (Fig. 6C).
A Combination of HDAC Inhibitor and Fas Antibody Induces Apoptosis
in Oncogenic Kras Cells. DNA methylation on CpG motifs in gene
promoters is often accompanied by the recruitment of HDACs to
the transcriptional regulatory site, thereby altering local chromatin
structure and inhibiting transcription. General inhibitors of class I
and II HDACs, alone or in combination with the methylation
Fig. 4. Kras knockout mouse NSCLC cells are sensitive to Fas-mediated apo-
ptosis. (A) FACS histogram showing the Fas receptor expression in Kras−/− and
KrasG12D/+ cells. (B) Fas-activating antibodies (Jo2) induces apoptosis in Kras−/−
but not KrasG12D/+ cells. Cells were incubated with Jo2 for 24 h. Bright-field
images show floating apoptotic Kras−/− cells (Lower Right). (C) Dot plot
showing the percentage of Annexin V- or propidium iodide (PI)-positive Kras−/−
and KrasG12D/+ cells. Red circle denotes Annexin V-positive cells. x and y axes
denote Annexin V and PI signals. (D) Quantitation of Annexin V-positive cells
represented as percentage of apoptotic cells. Error bars are SD (n = 3).
Fig. 5. KRAS knockout human NSCLC cells are sensitive to FAS-mediated
apoptosis. (A) CRISPR-mediated KRAS editing in human NSCLC cell line A549
with a homozygous G12S mutation. Pooled cells expressing sgKRAS were
analyzed by immunoblot to detect total KRAS protein level. HSP90 was used
as a loading control. (B) qPCR measurement of FAS mRNA in control and
sgRNA-expressing cells. (C) FACS histogram showing the levels of human FAS
receptor in A549 control or sgKRAS cells. (D) Representative bright-field
images showing floating apoptotic cells, in the presence of an activating
antibody recognizing human FAS receptor. (E) Dot plot showing percentage
of Annexin V- or PI-positive cells. Red circle denotes Annexin V-positive cells.
(F) Quantification of E. Error bars represent SD (n = 3).
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inhibitor 5-azacitydine, or its congener 5-aza-deoxycytidine (5Aza)
are being studied in clinical trials for treatment of diverse types of
tumors (43). Furthermore, HDAC inhibitors alone can induce
promoter de-methylation and de-repression (44). Because Kras-
directed epigenetic silencing of Fas also requires HDACs (45), we
asked whether DNA methylation inhibitors 5Aza or HDAC in-
hibitors such as Trichostatin A (TSA) or suberoylanilide hydroxamic
acid (SAHA) can restore Fas expression in KrasG12D/+ cells. All of
these inhibitors significantly increased Fas mRNA expression in
KrasG12D/+ mouse lung cancer cells (Fig. 7A). Furthermore, two
pan-HDAC inhibitors TSA and SAHA both significantly up-reg-
ulated Fas receptor level on the cell surface (Fig. 7B). Finally, we
observed that TSA or SAHA pretreatment sensitized KrasG12D/+
cells to Fas-mediated apoptosis in combination with Jo2 antibody
(Fig. 7 C and D, and Fig. S7). These results suggest that exploiting
the Fas activation as an Achilles’ heel in oncogenic Kras cells
using HDAC inhibitors can potentially provide a complementary
approach to Kras inhibitors.
Discussion
Herein, we report CRISPR/Cas9-mediated genome editing of
Kras in mouse and human lung cancer cells.
CRISPR Can Effectively Model Genetic Deletion of Oncogenes. Tradi-
tional technologies have limited ability to model complete si-
lencing of oncogenes because of the low efficiency of homologous
recombination without DNA breaks (18, 22). The CRISPR sys-
tem is flexible and provides a rapid and facile genetic system to
functionally investigate mechanisms of both KRAS and other
“undruggable” oncogenes in lung cancer pathology. Using CRISPR
to model genetic disruption of oncogenes will pave the road for
identifying therapeutic targets (22, 23).
Cancer Cells Can Escape KRAS Oncogene Addiction and Survive
Independent of KRAS. Cancer therapy can be improved by specifi-
cally modulating genes in resistance pathways. However, resistance
to KRAS-targeted therapy is unknown due to the lack of effective
small-molecule inhibitors for KRAS (16). Our data uncover KRAS
independence upon complete KRAS knockout, which is consistent
with our previous report that Kras mutant lung tumor can escape
from RNAi-mediated Kras knockdown (16). Although KRAS
knockout cells exhibited decreased colony formation ability, these
cells are viable, implying mechanisms of resistance to KRAS in-
hibition or depletion. The recovery of tumors in the absence of Kras
activity indicates potential resistance mechanisms to Ras inhibitors.
Inhibiting KRAS alone, therefore, might be insufficient for treating
KRAS-driven cancer in humans.
RNA-seq revealed a number of differentially expressed genes
between oncogenic Kras and Kras knockout cells (Fig. 2). Un-
derstanding additional mechanisms of KRAS independence will
be critical for tailoring treatment decisions in future generations of
KRAS inhibitors being developed by the RAS initiative at the
National Cancer Institute (3–5). Moreover, because we used
KrasG12D/+;p53−/− mouse lung cancer cells, it remains unclear how
additional genetic lesions (e.g., p53−/−) contribute to Kras in-
dependence. Future work is needed to investigate how Kras in-
dependence is affected by various genetic contexts.
Fas as an Achilles’ Heel in Kras-Independent Cells. Because KRAS-
independent cells are selectively sensitive to FAS-mediated apo-
ptosis, understanding how KRAS regulates FAS might unveil
treatment targets. Potential therapeutic options (such as siRNA)
might exploit these targets to improve the efficacy of KRAS in-
hibitors. Moreover, a better understanding of the epigenetic regu-
lation of FAS might allow us to turn FAS on and exploit it in other
cancer types. Additional studies are also needed to determine
whether Fas activation could mediate rejection of Ras-deficient
tumor cells during early stages of lung tumor or organ development.
Tumor-Targeted Fas Activation Is Required in Vivo. Our results
suggest that a Fas-activating antibody can selectively induce
apoptosis in Kras knockout cells. However, normal somatic cells
also express Fas receptor. For example, hepatocytes are highly
sensitive to FAS-mediated apoptosis; the systemic injection of
high-dose Jo2 antibody induces apoptosis in the liver (28). Thus,
Fig. 6. KRAS knockout DLD1 cells are sensitive to FAS-mediated apoptosis.
(A) KRAS knockout (KRAS−/+) and parent KRASG13D/+ DLD1 cells were in-
cubated with an activating antibody against human FAS. Representative
bright-field images show floating/apoptotic KRAS−/+ cells. (B) Quantitation of
apoptosis measured by Annexin V/PI staining and FACS analysis. Error bars are
SD (n = 3). (C) A simplified model of how KRAS silencing may increase FAS
expression and sensitize cells to FAS receptor-mediated apoptosis.
Fig. 7. A combination of HDAC inhibitor and Fas antibody induces apoptosis
in oncogenic Kras cells. (A) qPCR showing reactivation of Fas in KrasG12D/+
mouse KP lung cancer cells treated with 5-Aza (5 μM), TSA (10 nM), and SAHA
(10 μM) for 48 h. DMSO control is set to 1. (B) Representative FACS histogram
showing Fas expression on cell surface in the presence of TSA or SAHA.
(C) FACS dot plot showing induction of apoptosis by Jo2 antibody in KrasG12D/+
cells pretreated with TSA. (D) Quantitation of apoptosis measured by Annexin
V/PI staining and FACS analysis. Error bars are SD (n = 3). ***P < 0.001.
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FAS-activating antibody needs to be specifically delivered to tu-
mor cells to avoid liver damage. Future studies will explore ways to
tackle this challenge together with KRAS silencing. It may also be
that endogenous FAS ligand excreted from tumor microenviron-
ment can modulate apoptosis upon KRAS silencing in vivo.
In conclusion, our study has pinpointed FAS activation as a
potential strategy to improve the efficacy of future KRAS inhibi-
tors. Because KRAS mutations are prevalent in lung, colon, and
pancreatic cancer and are associated with poor patient outcomes,
these findings will be critical for developing effective ways to in-
hibit KRAS and prevent tumor relapse.
Materials and Methods
Vectors and Cloning. sgRNAs targeting mouse KrasG12D or human KRAS were
designed using Broad Institute online tool (https://www.broadinstitute.org/
rnai/public/analysis-tools/sgrna-design). The following sgRNA sequences were
used: mouse KrasG12D, 5′-GTGGTTGGAGCTGATGGCGT-3′, and human KRAS,
5′-GTAGTTGGAGCTGATGGCGT-3′. Oligos were annealed and cloned into the
lenti.U6sgRNA.Cas9-2A-Puro vector using a standard BsmBI protocol. WZL-
Hygro (Addgene; 18750) or WZL-HRAS-V12 (40) were gifts from Scott Lowe,
Memorial Sloan Kettering Cancer Center, New York.
ChIP Assays. ChIP assays were performed as previously described (26) using
DNMT1 (Abcam), EZH2 (CST) and H3K27me3 (Millipore), and H3K4Ac (Abcam)
antibodies. ChIP products were analyzed by qRT-PCR using Fas promoter
primer sets (Tables S1 and S2) corresponding to transcription start site (TSS) for
EZH2, H3K27me3, and ∼1 kb upstream of TSS for DNMT1. Samples were
normalized to input DNA, results were analyzed using the ΔΔCt method, and
fold enrichment at target site was calculated with respect to IgG control.
Quantitative PCR. Total RNA was purified using an RNeasy Mini Kit (74104;
Qiagen). Reverse transcription was performed and diluted cDNA was used as
template for real-time PCR. TaqMan probes or SYBG primers were used to
measure expression of mouse or human Fas (Tables S1 and S2).
Immunoblot Analysis. Cells were harvested and lysed in RIPA buffer with pro-
teinase and phosphatase inhibitors. Cell lysate was quantified and equal
amounts of protein were loaded into a 4–12% NuPage Bis-Tris gel (Life
Technologies). The proteins isolated by the gel was then transferred to ni-
trocellulose membrane, blocked with blocking buffer (Odyssey), and then in-
cubated with antibody against KRAS (sc-30; Santa Cruz) and Fas (Upstate;
05-351) overnight at 4 °C. An immunofluorescent secondary antibody (LICOR)
was used for the Odyssey Imaging machine.
Statistical Analysis. All quantitation data were collected from at least three
independent experiments, and the difference between groups were de-
termined using two-tailed Student’s t test, with P < 0.05 considered to be
significant. All animal study protocols were approved by the University of
Massachusetts Institutional Animal Care and Use Committee.
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